Company Statements

Biocon Biologics  /  Company Statements

Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification

  • Posted by: Biocon Biologics

Biocon Biologics Receives EIR from U.S. FDA for Two Manufacturing Facilities, Inspection Stands Closed

  • Posted by: Biocon Biologics

Biocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed

  • Posted by: Biocon Biologics

Biocon’s Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection

  • Posted by: Biocon Biologics

U.S. FDA Completes Pre-Approval Inspection of Two New Biocon Biologics Facilities in Bengaluru

  • Posted by: Biocon Biologics

U.S. FDA Issues Complete Response Letter for New Drug Application for Insulin Glargine; Commercialization Plans Remain Unchanged

  • Posted by: Biocon Biologics

U.S. FDA completes surveillance (routine) cGMP inspection of one of our Biologics Drug Product facilities in Bengaluru

  • Posted by: Biocon Biologics

Pre-Approval U.S. FDA Inspection Conducted at Biocon’s Insulins Facilities in Malaysia

  • Posted by: Biocon Biologics

Biocon Biologics Facilities in Bengaluru Receive EU GMP Certification

  • Posted by: Biocon Biologics

Biocon Facility Completes Pre Approval U.S. FDA Inspection

  • Posted by: Biocon Biologics
Share
buy twitter followers - omegle - SOL sniper bot - marsbahis güncel giriş